Sunesis Pharmaceuticals (SNSS) Upgraded at Zacks Investment Research
Sunesis Pharmaceuticals (NASDAQ:SNSS) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Saturday. The firm presently has a $0.75 target price on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price suggests a potential upside of 2.05% from the company’s current price.
According to Zacks, “Sunesis Pharmaceuticals is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel small molecule therapeutics for oncology and other serious diseases. It has built a broad product candidate portfolio through internal discovery and in-licensing of novel cancer therapeutics. It is advancing its product candidates through in-house research and development efforts and strategic collaborations with leading pharmaceutical and biopharmaceutical companies. “
SNSS has been the subject of a number of other research reports. ValuEngine upgraded shares of Sunesis Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Wednesday, January 2nd. HC Wainwright began coverage on shares of Sunesis Pharmaceuticals in a report on Thursday, December 20th. They issued a “neutral” rating and a $0.50 price objective for the company. Four research analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. Sunesis Pharmaceuticals has an average rating of “Hold” and a consensus price target of $1.75.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last announced its quarterly earnings data on Monday, November 5th. The biopharmaceutical company reported ($0.18) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.04. Equities analysts forecast that Sunesis Pharmaceuticals will post -0.81 earnings per share for the current fiscal year.
Sunesis Pharmaceuticals Company Profile
Sunesis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of oncology therapeutics for the treatment of solid and hematologic cancers. Its lead program is vecabrutinib, a non-covalently binding inhibitor of Bruton's tyrosine kinase (BTK), which is in Phase 1b/2 clinical trial in B-cell malignancies.
Featured Story: What are earnings reports?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Sunesis Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.